Trial Profile
A prospective, multicentre, comparative, double blind, randomized phase III study to assess immunogenicity and safety of LBVW0101 (Diphtheria-Tetanus-whole cell Pertussis- Hepatitis B) compared with Tritanrix HB (Diphtheria-Tetanus-whole cell Pertussis-Hepatitis B) and to demonstrate the equivalence of three different lots of LBVW0101, in terms of immunogenicity, in healthy infants at six, ten, and fourteen weeks of age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2016
Price :
$35
*
At a glance
- Drugs DTP-hepatitis B vaccine (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors LG Life Sciences
- 06 Jul 2010 New trial record